login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Single atrial fibrillation ablation procedure achieves high pulmonary vein isolation rates, study shows


Friday, 20 Jan 2012 15:14
HeartLight EAS
HeartLight EAS


A new study demonstrates the high acute and chronic success rates achievable with a single atrial fibrillation ablation procedure using the HeartLight endoscopic ablation system (CardioFocus). The study was conducted by Boris Schmidt and colleagues at Cardioangiologisches Centrum Bethanien, Frankfurt, Germany, and was published online in the Journal of Cardiovascular Electrophysiology, in January 2012. 


In the study, “Visually guided sequential pulmonary vein isolation: Insights into techniques and predictors of acute success,” Schmidt and colleagues performed ablation with a single HeartLight endoscopic ablation system (CardioFocus) and single transseptal puncture on 35 patients with drug-refractory paroxysmal or persistent atrial fibrillation. Pulmonary vein isolation was achieved in 70% (96/137) of veins with an initial ablation. After assessment with a circular mapping catheter, continued ablation with the same HeartLight device resulted in an overall 98% single procedure pulmonary vein isolation rate.


“Pulmonary vein isolation is a critical indicator of success in catheter ablation procedures for atrial fibrillation; however, this has traditionally been a very challenging and complex endeavor requiring an experienced operator, multiple ablation devices to account for varied patient anatomy, and even multiple transseptal punctures for access,” said Schmidt. “In this study we set out to examine the feasibility of performing a streamlined, visually-guided ablation procedure and record best practices to achieve endpoints of acute and chronic success. Our findings demonstrate that this unique approach to ablation may prove highly effective in treating atrial fibrillation patients.”


Procedures were performed in a mean time of 154± 38 min, with the ablation stage lasting an average of 89± 16 min and mean fluoroscopy time of 16 ± 6 min. Notably, between the first and last 12 cases a reduction in procedure time was observed (175 ± 48 min vs. 138 ± 26 min). The primary efficacy endpoint of the study was acute pulmonary vein isolation, with a secondary endpoint of freedom from atrial fibrillation between 90 and 365 days post-ablation and off antiarrythmic drugs. During a median follow-up of 266 days, 77% (27/35) of patients remained free of any tachyarrhythmia recurrence and off drugs.


“With the increasing use of catheter ablation as a treatment option for atrial fibrillation patients, the short learning curve and simplified approach enabled by the HeartLight EAS makes this a very promising system, especially as the technique continues to be adopted outside specialised ablation centres,” said Schmidt. “In the paper we documented our approach to performing ablation on our centre’s first series of patients to undergo treatment with the HeartLight EAS, and we believe that as the procedure continues to be standardised, additional centres will experience these impressive, reproducible results.”


About the HeartLight endoscopic ablation system


The HeartLight EAS is a catheter ablation system that incorporates, for the first time, an endoscope for direct visualisation of a beating heart, in real-time and without radiation. It also includes a compliant, dynamically adjustable balloon catheter designed for improved contact with the pulmonary vein ostium (opening) irrespective of the individual patient anatomy, and utilises laser energy for more efficient, durable and precise ablation treatment.


HearhLight is commercially available in Europe. The device is investigational in the USA, with a pivotal study expected to commence in 2012.

 




Add New Comment

Most popular


New bidirectional mechanical lead extraction device is safe and efficient with high success rates in long implanted leads
Thursday, 17 Mar 2016
A new bidirectional rotational mechanical lead extraction sheath is both safe and effective in performing lead extraction, according to a study published online ahead-of-print in Europace. Clinical ... New bidirectional mechanical lead extraction device is safe and efficient with high success rates in long implanted leads

First leadless pacemaker approved in the USA
Wednesday, 06 Apr 2016
Medtronic has announced it has received US Food and Drug Administration (FDA) approval for its Micra Transcatheter Pacing System (TPS). The leadless device, which is 93% smaller than conventional ... First leadless pacemaker approved in the USA

FDA proposes ban on most powdered medical gloves
Tuesday, 22 Mar 2016
The US Food and Drug Administration has announced a proposal to ban most powdered gloves in the USA. While use of these gloves is decreasing, they pose an unreasonable and substantial risk of illness ... FDA proposes ban on most powdered medical gloves

Features


How innovation can unleash tremendous growth in the $3.4 billion AF ablation market
Monday, 29 Feb 2016
Shlomo Ben-Haim (London, UK), a professor of medicine and serial entrepreneur in the medical device industry, examines the drivers of expansion of the atrial fibrillation (AF) ablation market, the ... How innovation can unleash tremendous growth in the $3.4 billion AF ablation market

Hybrid and surgical atrial fibrillation ablation: Opportunity, threat or both?
Monday, 15 Feb 2016
Despite major advances in techniques and technology over the past 15 years, the clinical outcomes for catheter ablation in non-paroxysmal atrial fibrillation patients remain disappointing, write Tom W... Hybrid and surgical atrial fibrillation ablation: Opportunity, threat or both?

Profiles


Jonathan Kalman
Monday, 18 Jan 2016
A leading heart rhythm expert in Australia, Jonathan M Kalman directs both clinical and research ... Jonathan Kalman

Michael Glikson
Wednesday, 14 Oct 2015
Michael Glikson (Tel Hashomer, Israel) has contributed to the development of technologies for CRT, ... Michael Glikson

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions